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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to 
“Lactobacillus plantarum TENSIA® in the semi-hard Edam-type „heart 
cheese‟ of Harmony™” and maintenance of normal blood pressure 
pursuant to Article 13(5) of Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from E-piim production Ltd, submitted for authorisation of a health claim pursuant to 
Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Estonia, the EFSA Panel on 
Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation 
of a health claim related to “Lactobacillus plantarum TENSIA® in the semi-hard Edam-type “heart cheese” of 
Harmony™” and maintenance of normal blood pressure (BP). The food constituent L. plantarum TENSIA®, 
which is the subject of the health claim, is sufficiently characterised. The Panel considers that the maintenance of 
normal blood pressure is a beneficial physiological effect. The applicant provided 47 references which did not 
address the effects of L. plantarum TENSIA
®
 on BP. The Panel considers that no conclusions can be drawn from 
these references for the scientific substantiation of the claim. Two human randomised, double-blind, placebo-
controlled, intervention studies investigated the effect on BP of L. plantarum TENSIA
®
 consumed in Edam-type 
cheese for three and eight weeks. In weighing the evidence, the Panel took into account that only one human 
intervention study with important methodological limitations showed a BP-lowering effect of L. plantarum 
TENSIA
®
 consumed in the Edam-type “heart cheese” of Harmony™ when consumed daily for eight weeks, and 
that no evidence was provided for a mechanism by which L. plantarum TENSIA
®
 in the Edam-type “heart 
cheese” of Harmony™ could exert the claimed effect. The Panel concludes that a cause and effect relationship 
has not been established between the consumption of Lactobacillus plantarum TENSIA
®
in the semi-hard Edam-
type “heart cheese” of Harmony™ and maintenance of normal blood pressure. 
© European Food Safety Authority, 2014 
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SUMMARY 
Following an application from E-piim production Ltd, submitted for authorisation of a health claim 
pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Estonia, 
the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion 
on the scientific substantiation of a health claim related to “Lactobacillus plantarum TENSIA® in the 
semi-hard Edam-type “heart cheese” of Harmony™” and maintenance of normal blood pressure. 
The scope of the application was proposed to fall under a health claim based on newly developed 
scientific evidence. 
The food constituent that is the subject of the health claim is L. plantarum TENSIA
®
 in the semi-hard 
Edam-type “heart cheese” of Harmony™. The strain L. plantarum TENSIA® (DSM 21380) has been 
specified using phenotypic and genotypic methods. Data on the conditions of use, specifications, 
manufacturing process and bioavailability as well as information on the stability of the strain were 
provided. The Panel considers that L. plantarum TENSIA
®
, the food constituent which is the subject 
of the health claim, is sufficiently characterised. 
The claimed effect proposed by the applicant is “maintenance of cardio-vascular health through 
reduction of blood pressure”. The target population proposed by the applicant is the general 
population. The Panel notes that the claimed effect relates to the maintenance of normal blood 
pressure. The Panel considers that the maintenance of normal blood pressure is a beneficial 
physiological effect. 
The applicant provided 47 (27 human and 20 non-human) references which included human 
intervention studies, guidelines, narrative reviews, and in vitro studies that did not address the effects 
of L. plantarum TENSIA
®
 on blood pressure (BP). The Panel considers that no conclusions can be 
drawn from these references for the scientific substantiation of the claim.  
Two human randomised, double-blind, placebo-controlled, intervention studies investigated the effect 
of L. plantarum TENSIA
®
 consumed in Edam-type cheese for three and eight weeks on BP. In the 
eight-week study, 136 participants who fulfilled the inclusion criteria at screening were randomised to 
consume Edam-type cheese with or without L. plantarum TENSIA
®
. The Panel notes that 35 
participants among those randomised did not fulfil the inclusion/exclusion criteria at baseline. 
Between-group differences in long-term (eight weeks) change in systolic blood pressure (SBP) 
(primary outcome), in long-term change in diastolic blood pressure (DBP), and in short-term (one to 
four weeks and five to eight week) changes in SBP and DBP were analysed in different populations 
(i.e. intention to treat (ITT), “modified-ITT” (mITT), and per protocol (PP) populations). SBP 
significantly decreased in the test group compared with the control group from baseline to week 8 in 
the mITT, ITT and PP populations. Data were also analysed by a mixed model using the mixed 
procedure in SAS and selecting an unstructured covariance structure. In the ITT population a 
statistically significant treatment by time interaction between groups was observed for SBP and DBP 
from baseline to week 8, whereas no statistically significant effect of treatment over time was 
observed in the PP population for both SBP and DBP from baseline to week 8.  
The Panel notes that the different results obtained in the ITT, mITT and PP populations using the 
statistical analyses above can be explained by the low proportion of randomised participants who 
completed the protocol as planned in relation to the primary outcome (60 out of 136, 44 %), and this 
is an important limitation of the study, together with the fact that 35 of the randomised participants 
did not meet the inclusion criteria at baseline. The Panel considers that this study with important 
methodological limitations shows a blood pressure-lowering effect of L. plantarum TENSIA
®
 in the 
Edam-type “heart cheese” of Harmony™ when consumed daily for eight weeks. 
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In the three-week cross-over study, which had already been submitted in a previous application for the 
same claim, 90 participants were randomised to consume Edam-type cheese with or without 
L. plantarum TENSIA
®
 and 83 participants completed the trial. Changes in SBP and DBP were the 
primary outcomes of the study. No significant differences in SBP or DBP changes were observed 
between the intervention and control groups during the study. The Panel notes that this study does not 
show an effect of L. plantarum TENSIA
®
 in Edam-type cheese on BP when consumed for three 
weeks.  
The applicant indicated that the mechanisms by which L. plantarum TENSIA
®
 in the Edam-type 
“heart cheese” of Harmony™ could exert an effect on BP are probably complex and mainly related to 
the ability of the strain to produce metabolites (i.e. acetylcholine, angiotensin-converting enzyme-
inhibitory peptides, nitric oxide) with vasodilation activity. The applicant provided three unpublished 
in vitro studies and a patent to support the proposed mechanisms for the claimed effect. The Panel 
notes that no evidence was provided by the applicant for a mechanism by which L. plantarum 
TENSIA
®
 in the Edam-type “heart cheese” of Harmony™ could exert the claimed effect. 
In weighing the evidence, the Panel took into account that only one human intervention study with 
important methodological limitations showed a BP-lowering effect of L. plantarum TENSIA
®
 
consumed in the Edam-type “heart cheese” of Harmony™ when consumed daily for eight weeks, and 
that no evidence was provided for a mechanism by which L. plantarum TENSIA
®
 in the Edam-type 
“heart cheese” of Harmony™ could exert the claimed effect.  
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of Lactobacillus plantarum TENSIA
®
in the semi-hard Edam-type “heart cheese” of 
Harmony™ and maintenance of normal blood pressure. 
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BACKGROUND 
Regulation (EC) No 1924/2006
4
 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of 
this Regulation, are authorised in accordance with this Regulation, and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Article 13(5) of this 
Regulation lays down provisions for the addition of claims (other than those referring to the reduction 
of disease risk and to children‟s development and health) which are based on newly developed 
scientific evidence, or which include a request for the protection of proprietary data, to the 
Community list of permitted claims referred to in Article 13(3). 
According to Article 18 of this Regulation, an application for inclusion in the Community list of 
permitted claims referred to in Article 13(3) shall be submitted by the applicant to the national 
competent authority of a Member State, which will make the application and any supplementary 
information supplied by the applicant available to the European Food Safety Authority (EFSA). 
STEPS TAKEN BY EFSA 
 The application was received on 11/02/2014. 
 The scope of the application was proposed to fall under a health claim based on newly 
developed scientific evidence. 
 On 26/02/2014, during the validation process of the application, EFSA sent a request to the 
applicant to provide missing information. 
 On 27/03/2014, EFSA received the missing information as submitted by the applicant. 
 The scientific evaluation procedure started on 01/04/2014. 
 On 06/05/2014, the Working Group on Claims of the NDA Panel agreed on a list of questions 
for the applicant to provide additional information to accompany the application. The clock 
was stopped on 14/05/2014 in compliance with Article 18(3) of Regulation (EC) 
No 1924/2006. 
 On 27/05/2014, EFSA received the requested information and the clock was restarted. 
 On 08/07/2014, the Working Group on Claims of the NDA Panel agreed on a list of questions 
for the applicant to provide additional information to accompany the application. The clock 
was stopped on 14/07/2014 in compliance with Article 18(3) of Regulation (EC) 
No 1924/2006. 
 On 25/07/2014, EFSA received the requested information and the clock was restarted. 
 During its meeting on 18/09/2014, the NDA Panel, having evaluated the data submitted, 
adopted an opinion on the scientific substantiation of a health claim related to “Lactobacillus 
plantarum TENSIA
®
 in the semi-hard Edam-type „heart cheese‟ of Harmony™” and 
maintenance of normal blood pressure. 
TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with 
Article 16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
opinion on the scientific substantiation of a health claim related to: “Lactobacillus plantarum 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
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TENSIA
® 
in the semi-hard Edam-type „heart cheese‟ of Harmony™” and maintenance of normal 
blood pressure. 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation for the 
marketing of Lactobacillus plantarum TENSIA
®
 a positive assessment of its safety, nor a decision on 
whether Lactobacillus plantarum TENSIA
® 
is, or is not, classified as a foodstuff. It should be noted 
that such an assessment is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006. 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant‟s name and address: E-piim production Ltd. Pikk 16, Järva-Jaani, 73301, Järvamaa. 
Estonia. 
Food/constituent as stated by the applicant 
According to the applicant, the food and constituent for which a health claim is made is the semi-hard 
Edam-type Südamejuust (English translation: Heart cheese) of Harmony  brand comprising probiotic 
strain Lactobacillus plantarum TENSIA . 
Health relationship as claimed by the applicant 
According to the applicant, the claimed effect is maintenance of cardio-vascular health through 
reduction of blood pressure. 
Wording of the health claim as proposed by the applicant 
According to the applicant, regular, at least for eight week consumption of 50 g/day Lactobacillus 
plantarum TENSIA  comprising Südamejuust (English translation: Heart cheese) of the Harmony  
brand helps to maintain the cardio-vascular system/heart health through reduction of blood 
pressure/Symbol of heart/. 
Specific conditions of use as proposed by the applicant 
According to the applicant, the minimal amounts of 5 × 10
7 
viable microbial cells in 1 g of cheese 
should be present per 50 g daily intake (i.e. the daily dose of the Lactobacillus plantarum strain 
TENSIA  consumed with this amount of cheese is 2.5 × 10
9 
CFU). This quantity of cheese could be 
consumed as a part of a balanced diet.  
The target population proposed by the applicant is the general population. 
ASSESSMENT 
1. Characterisation of the food/constituent 
The food constituent that is the subject of the health claim is Lactobacillus plantarum TENSIA
®
 in 
the semi-hard Edam-type “heart cheese” of Harmony™. 
The bacterial strain L. plantarum TENSIA
® 
has been isolated from a faecal sample of a healthy one-
year-old Estonian child (Mikelsaar et al., 2002). 
The strain L. plantarum TENSIA
® 
(DSM 21380) species identity as well as strain characterisation 
have been determined by using phenotypic (carbohydrate fermentation profiles (API 50 CHL), 
enzymatic activities profile (API ZYM) and short chain fatty acid profile (gas chromatography)) and 
genotypic (Internal Transcribed Spacer-Polymerase Chain Reaction (ITS-PCR), 16S rRNA gene 
sequencing and sequence analyses, and agarose gel electrophoresis image after Random Amplification 
of Polymorphic DNA by PCR (RAPD-PCR)) methods. Data on the conditions of use, specifications, 
manufacturing process and bioavailability as well as information on the stability of the strain 
L. plantarum TENSIA
® 
in freeze-dried powder are provided in the application. 
Lactobacillus plantarum TENSIA
® 
and maintenance of normal blood pressure 
 
 
EFSA Journal 2014;12(10):3842 8 
The deposit of the strain at the German culture collection DSMZ (Deutsche Sammlung von 
Mikroorganismen und Zellkulturen) under deposit number DSM 21380 is indicated in the application. 
The strain is used in the manufacturing process of a soft Edam-type cheese where the L. plantarum 
strain TENSIA
® 
(10
6
 CFU/mL cheese milk) is used as adjunct starter. Detailed specifications of the 
manufacturing process, stability information (survival and viable stability of the strain), 
characteristics and composition of the cheese were provided by the applicant. 
The Panel considers that the food constituent L. plantarum TENSIA
®
, which is the subject of the 
health claim, is sufficiently characterised. 
2. Relevance of the claimed effect to human health 
The claimed effect proposed by the applicant is “maintenance of cardio-vascular health through 
reduction of blood pressure”. The target population proposed by the applicant is the general 
population. 
In the context of the scope of the application, which was submitted pursuant to Article 13(5) of the 
Regulation (EC) No 1924/2006, the Panel notes that the claimed effect relates to the maintenance of 
normal blood pressure. 
Blood pressure (BP) is the pressure (force per unit area) exerted by circulating blood on the walls of 
blood vessels. Elevated blood pressure, by convention above 140 mmHg (systolic) and/or 90 mmHg 
(diastolic), may compromise normal arterial and cardiac function. 
The Panel considers that the maintenance of normal blood pressure is a beneficial physiological 
effect. 
3. Scientific substantiation of the claimed effect 
The applicant performed a literature search in MEDLINE, PubMed and esp@cenet. Keywords 
included “blood pressure lowering, nitric oxide, polyamines, cardiovascular health, Lactobacillus 
plantarum, CVD and probiotics, lactobacilli, milk peptides, ACE inhibitors”. The search was limited 
to publications in English, Russian, and Estonian that were original research articles (peer-reviewed), 
reviews, consensus documents from 2000 onwards, or patent documents describing a relationship 
between lactobacilli, including L. plantarum, and blood pressure lowering and cardio-vascular health. 
The Panel notes that the literature search included terms such as L. plantarum and lactobacilli, but not 
L. plantarum TENSIA
®
 (DSM 21380) in particular.  
The applicant provided 47 (27 human and 20 non-human) references as being pertinent to the claim. 
These included four human intervention studies which investigated the effect of strains other than L. 
plantarum TENSIA
®
 on blood pressure (Hata et al., 1996; Inoue et al., 2003; Seppo et al., 2003; 
Aihara et al., 2005), as well as guidelines, narrative reviews and in vitro studies which did not address 
the effects of L. plantarum TENSIA
®
. The Panel considers that no conclusions can be drawn from 
these references for the scientific substantiation of the claim.  
Two human intervention studies investigated the effect of the strain L. plantarum TENSIA
®
 on blood 
pressure (BP) (Mikelsaar et al., 2012, 2013). 
The unpublished study by Mikelsaar et al. (2013) is a randomised, double-blind, placebo-controlled 
parallel intervention which investigated the effects of consuming 50 g/day of Edam-type cheese 
containing L. plantarum TENSIA
®
 (average daily dose of L. plantarum TENSIA
®
 = 2.5 × 10
9
 CFU) 
compared with the same amount of cheese without L. plantarum TENSIA
®
 on BP in volunteers aged 
18 to 65 years with high normal BP (systolic blood pressure (SBP) = 130-139 mmHg; diastolic blood 
Lactobacillus plantarum TENSIA
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pressure (DBP) = 85-89 mmHg) or grade 1 hypertension (SBP = 140-159 mmHg; DBP = 90-99 
mmHg) (ESC/ESH, 2013). Participants with SBP ≤ 129 mmHg or ≥ 160 mmHg and/or 
DBP ≤ 84 mmHg or ≥ 100 mmHg, as well as those who performed “extensive exercise” were 
excluded. The test and control cheeses, which were consumed daily for eight weeks, were distributed 
to participants at randomisation and at week 4. BP was measured at baseline, week 4 and week 8 by a 
nurse in one clinic centre. The study was conducted in two different time periods of the year (period I 
April–June 2012 and period II October–December 2012) owing to the difficulty in recruiting a 
sufficient number of subjects. Upon a request by EFSA for clarification on whether seasonal 
variations in BP may have affected the results of the study, the applicant indicated that randomisation 
was carried out in the two periods and that no influence was observed on SBP per treatment group and 
time period, and thus the period of randomisation was not taken into account in the statistical analysis.   
The primary outcome of the study was the long-term (eight weeks) change in SBP. Secondary 
outcomes were long-term changes in DBP, and short-term (one to four weeks and five to eight weeks) 
changes in SBP and DBP. Total cholesterol, low-density lipoprotein-cholesterol, triglycerides, body 
mass index and waist-hip ratio, among others, were assessed as explanatory outcomes. A t-test was 
used for the analysis of the primary outcome, and the Wilcoxon rank sum test was used for the 
analyses of the remaining outcomes. The Panel notes that no scientifically sound reason was provided 
by the applicant to justify this choice.  
A total of 136 participants who fulfilled the inclusion criteria at screening (visit 0) were randomised 
to consume the cheese with or without L. plantarum TENSIA
®
 (n = 68 per group). Randomisation 
was stratified by age and sex. The Panel notes that, among the 136 participants randomised (intention 
to treat (ITT) population), 35 did not fulfil the inclusion/exclusion criteria at baseline (visit 1). The 
“modified” ITT (mITT) population was defined as all randomised participants with at least one 
primary variable measurement after baseline and no major protocol violations (n = 113, 57 and 56 in 
the test and control groups, respectively). The per protocol (PP) population was defined as all 
randomised participants meeting the inclusion/exclusion criteria at baseline who had valid endpoint 
measurements in addition to baseline and no major protocol violations. Upon a request by EFSA for 
clarification on the number of participants in each study group with complete data sets and who 
complied with the study protocol as planned, the applicant indicated that 60 participants (n = 32 in the 
test group and n = 28 in the control group) had complete data sets for BP measurements. Upon a 
request by EFSA for clarification on the compliance in the study, the applicant indicated that 
compliance with the study products was assessed using a questionnaire and quantitative PCR analysis 
of stools, which were collected in both study groups but analysed in only the test group.  
Between-group differences in SBP and DBP changes throughout the study were analysed for the 
mITT population. SBP and DBP measured at baseline and at weeks 4 and 8 were not statistically 
different between groups. SBP significantly decreased in the test group (by 6.66 mmHg) compared 
with the control group (by 2.56 mmHg; p = 0.007) from baseline to week 8. Upon a request by EFSA 
for clarification, the applicant stated that a significant difference for the primary outcome was also 
observed using a non-parametric test (Wilcoxon test: p = 0.008). DBP significantly decreased in the 
test group (by 4.34 mmHg) compared with the control group (by 1.21 mmHg; p = 0.026) from 
baseline to week 8. SBP and DBP did not change significantly between baseline and week 4 in the test 
group compared with the control, whereas DBP (but not SBP) significantly decreased between weeks 
4 and 8 in the test group (by 2.84 mmHg) compared with the control group (+0.24 mmHg; p = 0.002). 
Upon a request by EFSA for clarification on the reason for not using the ITT population for data 
analyses, the applicant stated that the use of the mITT population was preferred as important 
violations occurred in the ITT population, owing to the use of antibiotics and missing information at 
weeks 4 and 8. 
Upon a request by EFSA, the applicant provided a sensitivity analysis using the ITT and PP 
populations for changes in SBP and DBP during the study. In the ITT population, SBP decreased by 
6.81 mmHg in the test group and by 2.52 mmHg in the control group (p = 0.004), and, in the PP 
Lactobacillus plantarum TENSIA
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population SBP decreased by 7.76 mmHg in the test group and by 3.31 mmHg in the control group 
(p = 0.021). The Panel notes that this analysis for the ITT population was based on 120 participants, 
and not on the 136 randomised participants. Data were also analysed by a mixed model using the 
mixed procedure in SAS and selecting an unstructured covariance structure. In the ITT population a 
statistically significant treatment by time interaction was observed for SBP (p = 0.025) with a 
difference in change from baseline to week 8 between groups of 3.86 mmHg (standard error 
(SE) = 1.44 mmHg; p = 0.008), whereas no statistically significant effect of treatment over time was 
observed in the PP population (p = 0.082). In the ITT population, a statistically significant treatment 
by time interaction was observed for DBP (p = 0.005), with a difference in change from baseline to 
week 8 between groups of –3.02 mmHg (SE = 1.22 mmHg; p = 0.015), whereas no statistically 
significant effect of treatment over time was observed in the PP population (p = 0.080).  
The Panel notes that the different results obtained in the ITT, mITT and PP populations using the 
statistical analyses above can be explained by the low proportion of randomised participants who 
completed the protocol as planned in relation to the primary outcome (60 out of 136, 44 %), and this 
is an important limitation of the study, together with the fact that 35 of the randomised participants 
did not meet the inclusion criteria at baseline. The Panel considers that this study with important 
methodological limitations shows a blood pressure-lowering effect of L. plantarum TENSIA
®
 in the 
Edam-type “heart cheese” of Harmony™ when consumed daily for eight weeks. 
The intervention study by Mikelsaar et al. (2012) had already been submitted in a previous application 
for the same claim as an unpublished study report (referred to as Mikelsaar et al. 2009b). The claim 
was assessed by the Panel with an unfavourable outcome (EFSA NDA Panel, 2011). Briefly, this 
randomised, double-blind, placebo-controlled, cross-over human intervention study investigated the 
effects of consuming 50 g/day of Edam-type cheese containing L. plantarum TENSIA
®
 compared 
with the same amount of cheese without L. plantarum TENSIA
®
 on BP in healthy volunteers aged 18 
to 65 years. The test and control cheeses were consumed daily for three weeks each with a washout 
period of two weeks in between. A total of 90 participants were randomised and 83 participants 
completed the trial. Changes in SBP and DBP were the primary outcomes of the study. No significant 
differences in SBP or DBP changes were observed between the intervention and control groups 
during the study. The Panel notes that this study does not show an effect of L. plantarum TENSIA
®
 in 
Edam-type cheese on BP when consumed for three weeks.  
Mechanism of action 
The applicant indicated that the mechanisms by which L. plantarum TENSIA
®
 in the Edam-type 
“heart cheese” of Harmony™ could exert an effect on BP are probably complex and mainly related to 
the ability of the strain to produce metabolites (i.e. acetylcholine (Ach), angiotensin-converting 
enzyme (ACE) inhibitory peptides, nitric oxide (NO)) with vasodilation activity. The applicant 
provided three unpublished in vitro studies and a patent to support the proposed mechanisms for the 
claimed effect (Kilk, 2012; Mahlapuu and Rätsep, 2012; Songisepp et al. 2012; Ehrlich and Kilk, 
2013). 
The study by Mahlapuu and Rätsep (2012), reported significantly higher ACE-inhibitory activity of 
cow‟s milk fermented with L. plantarum TENSIA® than of control milk. The study by Ehrlich and 
Kilk (2013) investigated the ACE-inhibitory activity, and the concentration of some peptides, 
γ-aminobutyric acid (GABA) and Ach in a Südamejuust Harmony™ cheese prepared with 
L. plantarum TENSIA
®
 as adjunct starter in a freeze-dried or liquid form compared with regular 
Edam-type cheese after one and four months of ripening. This study reported no statistical difference 
in the ACE-inhibitory activity between the test and control cheeses. Concentrations of other 
substances with a presumed vascular activity (i.e. the peptides isoleucine–proline–proline 
(Ile-Pro-Pro), valine–proline–proline (Val–Pro–Pro), phenylalanine–leucine (Phe–Leu), isoleucine–
leucine (Ile-Leu), Ach, and GABA) in the intervention and control cheeses after one and four months 
of ripening did not follow a clear pattern. The study by Kilk (2012) reported a high concentration of 
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Ach in Südamejuust Harmony™ cheese with L. plantarum TENSIA® compared with Edam-type 
control cheese. No significant difference was observed in the concentration of the tripeptides Ile–Pro–
Pro and Val–Pro–Pro between the test and control cheese, whereas a higher amount of Ile–Leu, Phe–
Leu and isoleucine–proline–tyrosine was detected in the control cheese than in the test cheese. The 
applicant acknowledged that the biological significance of the peptides detected in the L. plantarum 
TENSIA
® 
cheese has not been identified. Information on the in vitro production of NO and 
polyamines such as putrescine and N8-acetylspermidine by the strain L. plantarum TENSIA
®
 was 
available in the patent provided by the applicant (Songisepp et al. 2012).  
The Panel notes that no evidence was provided by the applicant for a mechanism by which 
L. plantarum TENSIA
®
 in the Edam-type “heart cheese” of Harmony™ could exert the claimed 
effect. 
Weighing of the evidence 
In weighing the evidence, the Panel took into account that only one human intervention study with 
important methodological limitations showed a BP-lowering effect of L. plantarum TENSIA
®
 
consumed in the Edam-type “heart cheese” of Harmony™ when consumed daily for eight weeks, and 
that no evidence was provided for a mechanism by which L. plantarum TENSIA
®
 in the Edam-type 
“heart cheese” of Harmony™ could exert the claimed effect.  
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of Lactobacillus plantarum TENSIA
®
in the semi-hard Edam-type “heart cheese” of 
Harmony™ and maintenance of normal blood pressure. 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 The food constituent Lactobacillus plantarum TENSIA®, which is the subject of the health 
claim, is sufficiently characterised. 
 The claimed effect proposed by the applicant is “maintenance of cardio-vascular health 
through reduction of blood pressure”. The target population proposed by the applicant is the 
general population. Maintenance of normal blood pressure is a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of 
Lactobacillus plantarum TENSIA
® 
in the semi-hard Edam-type “heart cheese” of Harmony™ 
and maintenance of normal blood pressure. 
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on “Lactobacillus plantarum TENSIA® in the semi-hard Edam-type „heart 
cheese‟ of Harmony™” and maintenance of normal blood pressure pursuant to Article 13(5) of 
Regulation (EC) No 1924/2006 (Claim serial No: 0411_EE). February 2014. Submitted by E-piim 
production Ltd. 
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ABBREVIATIONS 
ACE  angiotensin converting enzyme 
Ach  acetylcholine 
BP  blood pressure 
CFU  colony-forming unit 
DBP  diastolic blood pressure 
GABA  γ-aminobutyric acid  
Ile-Leu  isoleucine–leucine 
Ile-Pro-Pro isoleucine–proline–proline 
ITT  intention to treat 
NO  nitric oxide 
Phe–Leu phenylalanine–leucine 
PP  per protocol 
SBP  systolic blood pressure 
SE  standard error 
Val–Pro–Pro valine–proline–proline 
